Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies.

Literature DB >> 31564196

Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies.

Yining Zhao^1,2, Yumei Li^1,2, Xiaoqiong Wu^1,2, Li Li^1,2, Jiayu Liu^1,2, Yanlan Wang^1,2, Yue Liu^1,2, Qing Li^1,2, Zhong Wang^1,2.

Abstract

CD16a (FcγRIIIa) mediates the antibody dependent cellular cytotoxicity (ADCC) and is important for anti-tumor activities of many therapeutic antibodies. Bispecific antibody targeting natural killer (NK) cells has been studied for cancer therapy. In this work, anti-CD16a single-domain antibodies were identified from hCD16a immunized camel. Bispecific antibodies are then constructed by fusing these single domain antibodies with an anti-CEA single domain antibody. These bispecific antibodies can recruite NK cells to kill CEA-positive tumor cells, and inhibit tumor growth in vivo, suggesting that these anti-CD16a single domain antibodies are powerful tools to engaging NK cells for cancer therapy.

Entities: Disease Species

Keywords: CD16a; CEA; VHH; bispecific antibody; phage display; single domain antibody

Mesh：

Substances：

Year: 2019 PMID： 31564196 PMCID： PMC7012161 DOI： 10.1080/15384047.2019.1665953

Source DB: PubMed Journal: Cancer Biol Ther ISSN： 1538-4047 Impact factor: 4.742

36 in total

1. A novel bispecific antibody, BiSS, with potent anti-cancer activities.

Authors: Bin Dong; Changhua Zhou; Ping He; Jing Li; Siqi Chen; Ji Miao; Qing Li; Zhong Wang
Journal: Cancer Biol Ther Date: 2016-02-01 Impact factor: 4.742

2. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity.

Authors: O Mandelboim; P Malik; D M Davis; C H Jo; J E Boyson; J L Strominger
Journal: Proc Natl Acad Sci U S A Date: 1999-05-11 Impact factor: 11.205

3. Development of oligoclonal nanobodies for targeting the tumor-associated glycoprotein 72 antigen.

Authors: Zahra Sharifzadeh; Fatemeh Rahbarizadeh; Mohammad Ali Shokrgozar; Davoud Ahmadvand; Fereidoun Mahboudi; Fatemeh Rahimi Jamnani; Seyed Hamid Aghaee Bakhtiari
Journal: Mol Biotechnol Date: 2013-06 Impact factor: 2.695

4. Increasing the potency of neutralizing single-domain antibodies by functionalization with a CD11b/CD18 binding domain.

Authors: Martin A Rossotti; Andrés González-Techera; Julio Guarnaschelli; Lucia Yim; Ximena Camacho; Marcelo Fernández; Pablo Cabral; Carmen Leizagoyen; José A Chabalgoity; Gualberto González-Sapienza
Journal: MAbs Date: 2015 Impact factor: 5.857

5. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors.

Authors: M A Arndt; J Krauss; S M Kipriyanov; M Pfreundschuh; M Little
Journal: Blood Date: 1999-10-15 Impact factor: 22.113

6. Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sequence.

Authors: S Oikawa; H Nakazato; G Kosaki
Journal: Biochem Biophys Res Commun Date: 1987-01-30 Impact factor: 3.575

7. Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans.

Authors: Maria Amann; Matthias Friedrich; Petra Lutterbuese; Eva Vieser; Grit Lorenczewski; Laetitia Petersen; Klaus Brischwein; Peter Kufer; Roman Kischel; Patrick A Baeuerle; Bernd Schlereth
Journal: Cancer Immunol Immunother Date: 2008-07-02 Impact factor: 6.968

8. Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.

Authors: Caroline Rozan; Amélie Cornillon; Corinne Pétiard; Martine Chartier; Ghislaine Behar; Charlotte Boix; Brigitte Kerfelec; Bruno Robert; André Pèlegrin; Patrick Chames; Jean-Luc Teillaud; Daniel Baty
Journal: Mol Cancer Ther Date: 2013-06-11 Impact factor: 6.261

Review 9. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.

Authors: Kory L Alderson; Paul M Sondel
Journal: J Biomed Biotechnol Date: 2011-05-24

Review 10. Bispecific antibodies and their applications.

Authors: Gaowei Fan; Zujian Wang; Mingju Hao; Jinming Li
Journal: J Hematol Oncol Date: 2015-12-21 Impact factor: 17.388

7 in total

1. The antibody-binding Fc gamma receptor IIIa / CD16a is N-glycosylated with high occupancy at all five sites.

Authors: Elizabeth A Lampros; Paul G Kremer; Jesús S Aguilar Díaz de León; Elijah T Roberts; Maria Carolina Rodriguez Benavente; I Jonathan Amster; Adam W Barb
Journal: Curr Res Immunol Date: 2022-06-09

Review 2. Camelid Single-Domain Antibodies: Promises and Challenges as Lifesaving Treatments.

Authors: Mehdi Arbabi-Ghahroudi
Journal: Int J Mol Sci Date: 2022-04-30 Impact factor: 6.208

3. Single-domain antibody screening by isPLA-seq.

Authors: Yueyuan Yin; Fei Yan; Ruimin Zhou; Mingchen Li; Jinyi Ma; Zhe Liu; Zhenyi Ma
Journal: Life Sci Alliance Date: 2021-10-21

4. Macrophages activated by hepatitis B virus have distinct metabolic profiles and suppress the virus via IL-1β to downregulate PPARα and FOXO3.

Authors: Yumei Li; Yanwen Zhu; Shu Feng; Yuji Ishida; Tsu-Pei Chiu; Takeshi Saito; Sean Wang; David K Ann; Jing-Hsiung James Ou
Journal: Cell Rep Date: 2022-01-25 Impact factor: 9.423